Tsinghua and partners to develop neutralising antibodies against COVID-19

This article was originally published here

The parties, which have signed a partnership and license agreement, have agreed to discover, develop, manufacture, and commercialise fully human neutralising monoclonal antibodies to address the COVID-19 pandemic.

The post Tsinghua and partners to develop neutralising antibodies against COVID-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply